title: Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients.
abstract: Immunotherapy targeting programmed death receptor 1 and programmed death ligand 1 (PD-L1) has shown impressive antitumor efficacy in several solid cancers, including advanced hepatocellular carcinoma (HCC). Since response rates of various cancers to such immunotherapy appear to correlate with PD-L1 expression levels, several studies have examined whether PD-L1 expression correlates with HCC pathology and patient prognosis. In this paper, we analyzed the strength and limitations of a recent meta-analysis of associations of PD-L1 with HCC characteristics and patient prognosis.
authors.affiliation: Hepatobiliary Surgery Department.
authors.forename: Jian-Hong
authors.initials: JH
authors.lastname: Zhong
authors.affiliation: Experimental Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People's Republic of China.
authors.forename: Cheng-Piao
authors.initials: CP
authors.lastname: Luo
authors.affiliation: Experimental Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People's Republic of China.
authors.forename: Chun-Yan
authors.initials: CY
authors.lastname: Zhang
authors.affiliation: Hepatobiliary Surgery Department.
authors.forename: Le-Qun
authors.initials: LQ
authors.lastname: Li
keywords: hepatic resection; hepatocellular carcinoma; prognoses; programmed death ligand 1